The short answer
Myostatin and related ligands restrain skeletal muscle growth by signalling through activin type II receptors. Blocking those receptors removes the restraint. Nunn and colleagues reported in Molecular Metabolism in 2024 that this preserves muscle mass and enhances fat loss during GLP-1 receptor agonism.
Key facts
- Pathway
- Myostatin / activin signalling
- Target
- Activin type II receptors
- Normal role
- Restrains muscle growth
- Effect of blockade
- Muscle preserved or increased
- Additional reported effect
- Enhanced fat loss
- Mechanism paper
- Nunn 2024 (PMID 38218536)
Why a brake on muscle growth exists
Muscle is metabolically expensive to build and maintain. An organism that built muscle without limit would waste energy it might need elsewhere, so growth is actively restrained. Myostatin is the principal restraining signal, and animals lacking functional myostatin are markedly more muscular, which is what established the pathway's role.
How the signal is delivered
Myostatin and related ligands bind activin type II receptors on muscle cells, initiating signalling that suppresses protein synthesis and promotes degradation. Blocking the receptor rather than the ligand catches several ligands converging on the same point, which is why the receptor is the more effective intervention target.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The finding that made this interesting for obesity
Nunn and colleagues titled their 2024 Molecular Metabolism paper to state it directly: antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. The second half is the surprise. The intervention did not merely protect muscle while fat loss continued unchanged; it reportedly increased fat loss.
Why enhanced fat loss is plausible rather than convenient
Muscle is metabolically active tissue. Preserving or increasing it maintains resting energy expenditure that would otherwise fall as mass is lost. A larger metabolically active compartment burning more energy is a coherent route from muscle preservation to greater fat loss, and it makes the combination more than the sum of two separate effects.
Why the combination logic is compelling
Incretin agonism reduces intake and produces loss across compartments. Activin receptor blockade shifts which compartment the loss comes from. The two act on different mechanisms with no obvious overlap, which is the profile that makes a combination worth testing rather than redundant.
What remains unestablished
Whether any of this translates to human functional outcomes, and what blocking a growth-restraining pathway does over years. Preclinical mechanism and Phase 2 body composition data are not the same as demonstrated clinical benefit, and no compound in this class holds an authorisation for obesity anywhere.
Frequently asked questions
What does myostatin do?
It restrains skeletal muscle growth by signalling through activin type II receptors, suppressing protein synthesis and promoting degradation.
Why block the receptor rather than myostatin itself?
Several ligands converge on the same receptor, so blocking it catches more of the signalling than blocking one ligand.
Does it only preserve muscle?
Nunn 2024 reports it also enhances fat loss during GLP-1 agonism, plausibly because preserved muscle maintains resting energy expenditure.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedNunn E et al., Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism. Mol Metab 2024 (PMID 38218536)pubmed.ncbi.nlm.nih.gov
- PubMedHeymsfield SB et al., Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity. JAMA Netw Open 2021 (PMID 33439265)pubmed.ncbi.nlm.nih.gov
- PubMedNeeland IJ et al. Diabetes Obes Metab 2024 (PMID 38937282)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Taldefgrobep Alfa: A Second Route Into the Same PathwayA myostatin-directed agent now in a Phase 2 obesity trial. Why more than one compound is targeting the same pathway from different angles.
- The Endpoint Changes When the Patient Is Still GrowingAdult trials report percentage weight loss. Adolescent trials report percent change in BMI - because a growing child gaining height is not failing.
- STEP TEENS and What It Reported201 adolescents, 68 weeks, −16.1% BMI against +0.6% on placebo. The full result including the safety findings that get left out.
- What Is Actually Registered, and at What PhaseA Phase 3 in 160 adolescents aged 12-17, and a Phase 1 safety study in 28 children aged 6-11. The distinction matters for what results will mean.
- When Low Muscle and High Fat Occur TogetherA 2026 paper describes sarcopenic obesity in children using clinical data and a juvenile mouse model. Why the body composition question is sharper in the young.